The biosimilar Hyrimoz showed similar flare rates to Humira, but 25% of patients experienced adverse events, mainly injection site reactions. Injection pain, linked to Hyrimoz's citrate content and ...
FDA approval of generic pharmaceutical maker Sandoz’s Hyrimoz injection, a biosimilar for Humira, has the potential to “to expand access for millions,” according to a March 21 news release. The ...
(RTTNews) - Sandoz said that the citrate-free high-concentration formulation or HCF of its biosimilar Hyrimoz (adalimumab-adaz) injection will be available in the United States starting July 1.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results